EP2484359A4 - Heparanase activity inhibitor - Google Patents

Heparanase activity inhibitor

Info

Publication number
EP2484359A4
EP2484359A4 EP10820611.1A EP10820611A EP2484359A4 EP 2484359 A4 EP2484359 A4 EP 2484359A4 EP 10820611 A EP10820611 A EP 10820611A EP 2484359 A4 EP2484359 A4 EP 2484359A4
Authority
EP
European Patent Office
Prior art keywords
activity inhibitor
heparanase activity
heparanase
inhibitor
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10820611.1A
Other languages
German (de)
French (fr)
Other versions
EP2484359B1 (en
EP2484359A1 (en
Inventor
Shunsuke Iriyama
Hirotada Fukunishi
Masaru Suetsugu
Satoshi Amano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of EP2484359A1 publication Critical patent/EP2484359A1/en
Publication of EP2484359A4 publication Critical patent/EP2484359A4/en
Application granted granted Critical
Publication of EP2484359B1 publication Critical patent/EP2484359B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
EP10820611.1A 2009-09-30 2010-09-29 Heparanase activity inhibitor Active EP2484359B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009228406 2009-09-30
PCT/JP2010/066998 WO2011040496A1 (en) 2009-09-30 2010-09-29 Heparanase activity inhibitor

Publications (3)

Publication Number Publication Date
EP2484359A1 EP2484359A1 (en) 2012-08-08
EP2484359A4 true EP2484359A4 (en) 2015-07-08
EP2484359B1 EP2484359B1 (en) 2018-07-25

Family

ID=43826308

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10820611.1A Active EP2484359B1 (en) 2009-09-30 2010-09-29 Heparanase activity inhibitor

Country Status (12)

Country Link
US (2) US8609075B2 (en)
EP (1) EP2484359B1 (en)
JP (2) JP5593323B2 (en)
KR (1) KR101431348B1 (en)
CN (1) CN102655863B (en)
BR (1) BR112012007090A2 (en)
ES (1) ES2687780T3 (en)
HK (1) HK1171390A1 (en)
IN (1) IN2012DN02632A (en)
RU (1) RU2503454C1 (en)
TW (1) TWI461221B (en)
WO (1) WO2011040496A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5685369B2 (en) * 2009-09-15 2015-03-18 株式会社 資生堂 Whitening method with heparanase inhibitor and method for evaluating substances having whitening effect
JP2013032332A (en) * 2011-07-01 2013-02-14 Lintec Corp Immunoactivator
JP5258993B1 (en) * 2012-03-29 2013-08-07 株式会社 資生堂 Heparan sulfate production promoter
JP6321506B2 (en) * 2014-09-22 2018-05-09 株式会社 資生堂 Whitening method with heparanase inhibitor and method for evaluating substances having whitening effect
WO2018074606A1 (en) 2016-10-21 2018-04-26 株式会社資生堂 Laminin 511 production promoter, basal epidermal layer stabilizer and/or screening method for agent to minimize reduction in or promote increase in epidermal stem cells
BR112019012045A2 (en) 2016-12-13 2020-08-18 Beta Therapeutics Pty Ltd heparanase inhibitors and their use
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3381908A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase
EP3381897A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer
EP3381906A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Compounds for use as heparanase inhibitors
EP3381907A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Symmetrical 2-aminophenyl-benzazolyl-5-acetate compounds and their use as anti-heparanase
EP3381898A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Symmetrical tris-aryl-amide derivatives and their use as anti-heparanase
EP3388439A1 (en) 2017-04-11 2018-10-17 Leadiant Biosciences SA Biotin-conjugated n-acetyl glycol split heparin
EP3639821A4 (en) 2017-06-13 2021-03-17 National Cancer Center Carcinogenesis inhibitor
WO2020219753A1 (en) * 2019-04-24 2020-10-29 University Of Florida Research Foundation, Incorporated Heparanase compounds and methods of use
TW202237061A (en) 2020-12-15 2022-10-01 日商資生堂股份有限公司 Epidermal stem cell proliferation-promoting agent
WO2022131108A1 (en) * 2020-12-15 2022-06-23 株式会社 資生堂 Dermis regeneration promoter
WO2023100682A1 (en) * 2021-12-03 2023-06-08 株式会社 資生堂 Cosmetic
WO2023106123A1 (en) * 2021-12-09 2023-06-15 株式会社 資生堂 Cosmetic
WO2023106121A1 (en) * 2021-12-09 2023-06-15 株式会社 資生堂 Oil-in-water emulsion cosmetic
WO2023120180A1 (en) * 2021-12-20 2023-06-29 株式会社 資生堂 Oil-in-water type emulsified cosmetic
WO2023149225A1 (en) * 2022-02-03 2023-08-10 株式会社 資生堂 Skin care composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593038A (en) * 1985-04-03 1986-06-03 Burzynski Stanislaw R Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
US20030180237A1 (en) * 2002-02-15 2003-09-25 Goldschmidt Ag Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances
JP2008303185A (en) * 2007-06-08 2008-12-18 Shiseido Co Ltd Agent for promoting formation and maturation of cornified envelope
JP2008303187A (en) * 2007-06-08 2008-12-18 Shiseido Co Ltd Agent for promoting formation and maturation of cornified envelope
JP2008303186A (en) * 2007-06-08 2008-12-18 Shiseido Co Ltd Formation/maturation promotor of cornified envelope
EP2119429A1 (en) * 2008-05-14 2009-11-18 L'Oréal Cosmetic composition containing a dibenzoylmethane derivative and a pyrrolidinone derivative; method for photostabilising the dibenzoylmethane derivative

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1256235A (en) * 1917-03-31 1918-02-12 William F Jacobs Work-supporting horse.
US4049650A (en) 1976-10-18 1977-09-20 Morton-Norwich Products, Inc. 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones
US4731453A (en) 1985-04-03 1988-03-15 Mitsui Toatsu Chemicals, Inc. Process for producing 1, 3-dialkyl-2-imidazolidinone
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5011621A (en) 1990-06-04 1991-04-30 Arco Chemical Technology, Inc. Paint stripper compositions containing N-methyl-2-pyrrolidone and renewable resources
US5583256A (en) 1994-07-07 1996-12-10 Mitsui Toatsu Chemicals, Inc. Process for producing 1,3-dialkyl-2-imidazolidinone
US5837224A (en) 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
JPH11335235A (en) 1998-05-22 1999-12-07 Shiseido Co Ltd Antiaging agent
GB9913415D0 (en) 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
JP2001163794A (en) 1999-12-03 2001-06-19 Shiseido Co Ltd Promoter for production of hyaluronic acid and preparation for external use for skin
TWI233361B (en) 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
US20030129259A1 (en) * 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
CN101601702B (en) 2002-06-25 2012-04-18 株式会社资生堂 Anti-aging agent
AU2004273615B2 (en) * 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
WO2005051942A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
FR2873377B1 (en) * 2004-07-23 2006-10-13 Sanofi Synthelabo AZASUCRE DERIVATIVES, HEPARANASES INHIBITORS, PROCESS FOR THE PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
US7238260B2 (en) 2004-10-26 2007-07-03 Lyondell Chemical Technology, L.P. Purification of N-(2-hydroxyethyl)-2-pyrrolidone
JP2006303185A (en) 2005-04-20 2006-11-02 Matsushita Electric Ind Co Ltd Semiconductor device and its manufacturing method
JP2007277149A (en) * 2006-04-06 2007-10-25 Kao Corp Involucrin expression promoter
US8097581B2 (en) * 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
CN101311188B (en) * 2007-05-21 2010-12-29 中国人民解放军军事医学科学院生物工程研究所 Small molecule peptides inhibitor of human heparinase
CN101983051B (en) 2008-03-31 2013-04-24 株式会社资生堂 Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method
WO2009122540A1 (en) * 2008-03-31 2009-10-08 株式会社資生堂 Wrinkle-preventing or improving agent for oral, injection or external skin application and cosmetic method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593038A (en) * 1985-04-03 1986-06-03 Burzynski Stanislaw R Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
US20030180237A1 (en) * 2002-02-15 2003-09-25 Goldschmidt Ag Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances
JP2008303185A (en) * 2007-06-08 2008-12-18 Shiseido Co Ltd Agent for promoting formation and maturation of cornified envelope
JP2008303187A (en) * 2007-06-08 2008-12-18 Shiseido Co Ltd Agent for promoting formation and maturation of cornified envelope
JP2008303186A (en) * 2007-06-08 2008-12-18 Shiseido Co Ltd Formation/maturation promotor of cornified envelope
EP2119429A1 (en) * 2008-05-14 2009-11-18 L'Oréal Cosmetic composition containing a dibenzoylmethane derivative and a pyrrolidinone derivative; method for photostabilising the dibenzoylmethane derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011040496A1 *

Also Published As

Publication number Publication date
TWI461221B (en) 2014-11-21
JP2014111640A (en) 2014-06-19
CN102655863B (en) 2013-11-20
US8901160B2 (en) 2014-12-02
JP5593323B2 (en) 2014-09-24
AU2010301641A1 (en) 2012-03-22
US20140080878A1 (en) 2014-03-20
KR20120060205A (en) 2012-06-11
RU2012117797A (en) 2013-11-10
JPWO2011040496A1 (en) 2013-02-28
EP2484359B1 (en) 2018-07-25
US20120183481A1 (en) 2012-07-19
CN102655863A (en) 2012-09-05
WO2011040496A1 (en) 2011-04-07
US8609075B2 (en) 2013-12-17
EP2484359A1 (en) 2012-08-08
IN2012DN02632A (en) 2015-09-04
KR101431348B1 (en) 2014-08-19
TW201117832A (en) 2011-06-01
HK1171390A1 (en) 2013-03-28
ES2687780T3 (en) 2018-10-29
BR112012007090A2 (en) 2018-06-05
RU2503454C1 (en) 2014-01-10

Similar Documents

Publication Publication Date Title
HK1171390A1 (en) Heparanase activity inhibitor
EP2391623A4 (en) Inhibitors of akt activity
EP2409270A4 (en) Account activity alert
HK1204227A1 (en) Benzamide derivatives
EP2443235A4 (en) ß-GLUCOSIDASE VARIANTS
EP2413932A4 (en) Inhibitors of akt activity
EP2406250A4 (en) Inhibitors of akt activity
EP2389068A4 (en) Hedgehog pathway inhibitors
IL220526A0 (en) Kokumi-imparting agent
EP2478768A4 (en) Anti-plant-virus agent
EP2519508A4 (en) Metalloenzyme inhibitor compounds
IL220527A0 (en) Kokumi-imparting agent
EP2405756A4 (en) Inhibitors of akt activity
HK1171013A1 (en) Inhibitors of akt activity akt
EP2514426A4 (en) Compounds having anti-inflammatory activity
GB0901898D0 (en) Dual calpain-ros inhibitors
GB0907886D0 (en) Corrosion inhibitor
EP2496230A4 (en) Ire-1 alpha inhibitors
EP2433502A4 (en) Bitterness-suppressing agent
GB0901900D0 (en) Dual calpain-ros inhibitors
EP2463292A4 (en) Compound having neurite-outgrowing activity
AU2010301641B2 (en) Heparanase activity inhibitor
EP2434392A4 (en) Processor
GB0906509D0 (en) Wok stabiliser
GB0906919D0 (en) Inhibitor complex structure

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150609

RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 19/02 20060101ALI20150602BHEP

Ipc: A61P 43/00 20060101ALI20150602BHEP

Ipc: A61K 8/49 20060101ALI20150602BHEP

Ipc: A61Q 19/08 20060101ALI20150602BHEP

Ipc: A61K 31/4166 20060101ALI20150602BHEP

Ipc: A61K 31/4015 20060101AFI20150602BHEP

17Q First examination report despatched

Effective date: 20160415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180209

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTC Intention to grant announced (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SHISEIDO COMPANY, LTD.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

INTG Intention to grant announced

Effective date: 20180618

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1021011

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010052231

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2687780

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20181029

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180725

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1021011

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181125

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181026

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181025

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181025

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010052231

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180930

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180929

26N No opposition filed

Effective date: 20190426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20190923

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180929

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20191004

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100929

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200929

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200930

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230521

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230823

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230822

Year of fee payment: 14

Ref country code: DE

Payment date: 20230822

Year of fee payment: 14